Clinical Trial: rBCG-N-RSV Vaccine in Adults Aged 60 Years and Older

U.S., Aug. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07762014) titled 'rBCG-N-RSV Vaccine in Adults Aged 60 Years and Older' on Aug. 02.

Brief Summary: This Phase 2 clinical study will evaluate the safety of the rBCG-N-RSV vaccine compared to conventional BCG in adults older than 60 years. It will also compare the cellular anti-mycobacterial immune response of both vaccines in adults older than 60 years and characterize the cellular immune response against RSV nucleoprotein (N) generated by the rBCG-N-RSV vaccine in adults older than 60 years as compared to the response induced by the conventional BCG.

Study Start Date: Sept. 07

Study Type: INTERVENTIONAL

Condition: Respiratory Syncytial Virus Infe...